Advertisement

Topics

Clinical Trials About "Epoetin Beta Chronic Kidney Failure" RSS

20:59 EDT 19th October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Epoetin Beta Chronic Kidney Failure" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Epoetin Beta Chronic Kidney Failure" on BioPortfolio

We have published hundreds of Epoetin Beta Chronic Kidney Failure news stories on BioPortfolio along with dozens of Epoetin Beta Chronic Kidney Failure Clinical Trials and PubMed Articles about Epoetin Beta Chronic Kidney Failure for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Epoetin Beta Chronic Kidney Failure Companies in our database. You can also find out about relevant Epoetin Beta Chronic Kidney Failure Drugs and Medications on this site too.

Showing "Epoetin Beta Chronic Kidney Failure" Clinical Trials 1–25 of 18,000+

Extremely Relevant

Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant

Main objective : Assessing the effect of epoetin beta on Hb rate and the glomerular filtration rate estimated 30 days after kidney transplant.


The Clinical Evaluation of the Dose of Erythropoietins Trial

Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are the most used treatment option. The purpose of this study is to determine the benefits and harms of different ESA doses therapeutic strategy for the management of anaemia of end stage kidney disease (ESKD).

A Study of Once Monthly Intravenous or Subcutaneous Mircera in Patients With Chronic Kidney Disease on Hemodialysis.

This 2 arm study will compare the hemoglobin maintenance with once monthly Mircera administration versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. Patients will be randomized to receive either monthly s.c. or i.v. Mircera (at a starting dose of 120 or 200 micrograms, calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered), or standard therapy (iv or sc epoetin beta once, twice or thrice we...


An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant

This observational study will investigate efficacy and safety of methoxy polyethyleneglycol-epoetin beta in participants with a kidney transplant. Data of each participant will be collected over 15 months of Mircera therapy.

Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects

A study to see how a single subcutaneous dose of Epoetin beta (NeoRecormon®) in healthy Japanese compares with a single subcutaneous dose of Epoetin beta (NeoRecormon®) in Caucasian Male subjects. Each subject received a single subcutaneous dose of 50IU/kg of NeoRecormon Multidose solution on Day 1.

COMETE Study: Comorbidity Mircera Evolution of Hemoglobin Rate; A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease

This prospective, multicenter, observational study will evaluate the impact of c omorbidity factors on the hemoglobin level in patients with chronic kidney disea se not on dialysis who are initiated on treatment with Mircera (methoxy polyethy lene glycol-epoetin beta). Data will be collected from patients for 9 months aft er initiation of Mircera treatment.

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

This study will assess the efficacy and safety of subcutaneous (sc) Mircera give n as maintenance treatment for renal anemia in chronic kidney disease patients o n dialysis who were previously receiving sc epoetin. The anticipated time on stu dy treatment is 1-2 years and the target sample size is 100-500 individuals.

An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis

This observational, prospective, multicenter study will describe the mean dose o f Mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels i n patients with chronic kidney disease. Patients are not on dialysis and are nai ve to, or have received erythropoiesis stimulating agent treatment. Data will be collected for 10 months.

A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis

This multicenter observational study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease not on dialysis in routine clinical practice. Eligible patients treated with Mircera for chronic renal anemia according to the standard of care and in line with the current local label will be followed for 6 months.

An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis

This prospective observational study will assess the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in clinical practice in patients with chronic kidney disease, in pre-dialysis or on dialysis, initiated on Mircera treatment. Data from each patient will be collected over 12 months of treatment.

Study of Erythropoietin (EPO) Administration Schedule

The purpose of this study is to compare the hemoglobin and hematocrit variability between once and three times weekly erythropoietin therapy for the anemia in patients with maintenance dialysis.

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

This 2 arm study will compare 'time and motion' (provider time spent on anemia management) and effect on hemoglobin levels, of Mircera and epoetin alfa, in anemic patients with chronic kidney disease (CKD) on hemodialysis. Patients stable on iv epoetin alfa will be randomized either to receive standard of care therapy (epoetin alfa iv 3 times weekly), or to receive Mircera 120-360 micrograms iv, monthly. After a titration period, average time spent on anemia treatment over a 3 ...

A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

The purpose of this study is to show that giving PROCRIT (Epoetin alfa) every 2 weeks to increase the hemoglobin (Hb) level and then to adjust the PROCRIT (Epoetin alfa) dose every 4 weeks (Q4W) to maintain Hb levels, is safe and effective in patients with anemia from Chronic Kidney Disease (CKD), not on dialysis, who reside in long-term care facilities. In this study the frequency of PROCRIT (Epoetin alfa) dosing is under investigation.

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

This study will assess the efficacy and safety of intravenous (iv) or subcutaneo us (sc) Mircera, administered with pre-filled syringes, as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previo usly receiving iv or sc epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer

RATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether epoetin alfa or epoetin beta are more effective when given with or without iron infusion in treating anemia in patients with cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa or epoetin beta to compare how well they work with or without iron infusion in treating ...

A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

This study will evaluate whether anemia prevention with NeoRecormon has an additional impact on reducing cardiovascular risk over conventional anemia treatment in patients mostly with stage IV chronic kidney disease and renal anemia. The anticipated time on study treatment is 2+ years and the target sample size is 500+ individuals.

A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.

This two arm study will compare the maintenance of hemoglobin levels, safety and tolerability of once every 4 weeks subcutaneous administration of Mircera versus epoetin beta in dialysis patients with chronic renal anemia. Patients will be randomized to receive either subcutaneous Mircera (starting dose 120, 200 or 360 micrograms) every 4 weeks or subcutaneous epoetin beta in accordance with the prescribed dosing information. In both groups, the starting dose will be the same a...

An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)

This prospective, multicenter, observational study will evaluate the impact of c omorbidities on hemoglobin stability in chronic kidney disease patients on dialy sis treated with Mircera (methoxy polyethylene glycol-epoetin beta). Eligible pa tients will be followed for 6 months of treatment.

OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Stages 3 & 4 Not on Dialysis

This prospective observational study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients not on dialysis with renal anemia. Patients initiated on treatment with Mircera according to the Summary of Product Characteristics and standard clinical practice will be followed for 10 months.

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

This study will assess the efficacy and safety of subcutaneous Mircera in the tr eatment of renal anemia in patients with chronic kidney disease who are not on d ialysis and not receiving epoetin or any other erythropoietic substance. The ant icipated time on study treatment is 1-2 years and the target sample size is 100- 500 individuals.

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen,) based on maintenance of hemoglobin (Hb) levels and study drug dose requirements, in patients treated for anemia associated with chronic renal failure and on hemodialysis.

A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis

This sequential study will assess the efficacy and safety of multiple doses of intravenous Mircera, and will determine the optimum starting dose for maintenance treatment of anemia in children with chronic kidney disease on hemodialysis. Pediatric patients will remain on epoetin alfa, epoetin beta or darbepoetin alfa during the screening period, after which they will receive intravenous Mircera monthly, at a starting dose related to the previous weekly epoetin or darbepoetin al...

An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia

This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients on dialysis receiving Mircera for the treatment of chronic renal anemia. Eligible patients will be followed for 24 weeks.

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

This single arm study will assess the efficacy and safety of intravenous Mircera, administered with pre-filled syringes, for the treatment of anemia in patients with chronic kidney disease who are on dialysis, and who have previously received treatment with epoetin alfa or beta or darbepoetin alfa. Patients will receive monthly intravenous injections of Mircera, with the starting dose derived from the dose of epoetin alfa or beta or darbepoetin they were receiving in the week p...


More From BioPortfolio on "Epoetin Beta Chronic Kidney Failure"

Advertisement
Quick Search
Advertisement
Advertisement